What the trial was testing
The trial enrolled 274 patients with atopic dermatitis. The study was sponsored by Kyowa Kirin and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
About 50-60% reduction in eczema severity vs. 15% in the comparison group.
The Lancet · 2023 · NCT03703102
These findings — that in eczema severity at 16 weeks on rocatinlimab in moderate-to-severe atopic dermatitis — were published in the The Lancet and represent the headline result of the study.
Researchers tracked outcomes across 274 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with atopic dermatitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Rocatinlimab is still in development and not yet FDA-approved as of early 2026. Several biologics for moderate-to-severe atopic dermatitis are FDA-approved and available now, including dupilumab (Dupixent), tralokinumab (Adbry), and lebrikizumab (Ebglyss). Ask a dermatologist about approved options or open trials.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open atopic dermatitis trials
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.
CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis
This is an open-label, randomised, comparative, prospective, interventional study of a cosmetic product.